Misonix announced the results of a retrospective, comparative study of its ultrasonic BoneScalpel and whether is has the potential to improve perioperative outcomes in decompression of thoracic spinal stenosis.
Here are five takeaways:
1. The retrospective study was conducted between 2013 and 2014, and a total of 100 consecutive cases were examined — 55 using BoneScalpel and 45 using conventional manual bone punches. The study was conducted by Ajay Krishnan, MBBS, of the Stavya Spine Hospital and Research Center in India. The results of the study have been submitted for publication in a scientific journal.
2. The study found that use of the BoneScalpel led to a reduction in dural tears and an absence of neurological worsening post surgery. Blood loss was reduced by 27.5 percent and total operative time was reduced by 22 percent. The operative time per spinal segment was reduced by 28.5 percent.
"All orthopedic surgeons are well familiar with the difference between a traditional plaster cutter and an oscillating cast saw. Likewise, the ultrasonic BoneScalpel is a precise, tissue-specific bone cutting tool, and in fact, a quite magical tool in my armamentarium. It has empowered me as a surgeon, making potentially dangerous thoracic spine procedures into more predictable, safer procedures with better patient outcomes," said Dr. Krishan.
3. Misonix designs, manufactures and markets therapeutic ultrasonic surgical devices for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery and laparoscopic surgery. It is actively involved in charitable work, and in 2013, it donated its ultrasonic BoneScalpel to the Uganda Spine Surgery Mission organized by spine surgeon Isador Lieberman, MD, from the Texas Back Institute in Plano.
4. The global spine surgery devices market is forecasted to be worth $14.8 billion by 2017, according to a MarketsandMarkets report. The market was valued at $11.5 billion in 2012 and estimated annual growth rate is 5.1 percent over the next five years.
5. Several device companies have recently released efficacy and safety study results for their products. Last week, VEXIM announced the results of an international clinical study on the clinical performance of SpineJack in treating acute traumatic vertebral compression fractures. Earlier in the month, Boston Scientific announced new retrospective data related to its Precision Spectra Spinal Cord Stimulator, which shows that it provides sustained and significant low-back pain relief six months after implementation.
More Articles on Devices:
5 Key Results: LDR's Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE's Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018